Ashish Talati Quoted in “FDA Concludes that CBD Needs its Own Regulatory Pathway”
Ashish Talati spoke with Nutritional Outlook’s Sebastian Krawiec about FDA’s conclusion that “a new regulatory pathway for CBD is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks.”
Ashish stated that the FDA did not come out and say CBD products currently sold in the market should be removed or that CBD products are dangerous. He expressed what the industry hoped for — a rulemaking to allow marketing of CBD products and, went on to say that what they got was a kick in the can, so to speak. Ashish’s view is that a new regulatory pathway is not needed because all the risk management reasons that FDA gave, such as prevention of contaminants, CBD content limits, etc., can be adequately addressed via existing regulations aimed at ensuring the safety and quality of products.
To read the full story, click here.
